相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour et al.
BLOOD (2011)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Elias Jabbour et al.
BLOOD (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam et al.
BLOOD (2008)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Current and emerging treatment options in chronic myeloid leukemia
Elias Jabbour et al.
CANCER (2007)
Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Hagop M. Kantarjian et al.
BLOOD (2006)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
Clinical resistance to imatinib: mechanisms and implications
A Hochhaus et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)